The FDA issued draft guidance outlining paths for validating New Approach Methodologies (NAMs) that can replace certain animal pharmacology and toxicology studies, signaling regulatory openness to human‑centric and mechanism‑based safety data. The guidance provides sponsors a framework to qualify alternative assays and models for early‑phase safety assessment. Separately, FDA and NIH communications highlighted milestones toward reducing reliance on animal testing, reflecting agency efforts to modernize toxicology and streamline drug development timelines. Industry and academic stakeholders say broader acceptance of NAMs could lower costs and accelerate candidate selection if validation pathways are clear and reproducible. The draft guidance invites stakeholder feedback and will require demonstration of human relevance, reproducibility, and regulatory‑grade validation before widespread adoption in pivotal submissions.